Boileve Alice, Smolenschi Cristina, Lambert Aurélien, Boige Valérie, Tarabay Anthony, Valery Marine, Fuerea Alina, Pudlarz Thomas, Conroy Thierry, Hollebecque Antoine, Ducreux Michel
Department of Medical, Gustave Roussy, Villejuif 94800, France.
Department of Medical Oncology, Institut de Cancérologie de Lorraine, Nancy 54519, France.
World J Gastrointest Oncol. 2024 Jul 15;16(7):2902-2914. doi: 10.4251/wjgo.v16.i7.2902.
Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in patient management due to a dismal prognosis, increasing incidence, and limited treatment options. In this regard, precision medicine, which personalizes treatments based on tumour molecular characteristics, has gained great interest. However, its widespread implementation is not fully endorsed in current recommendations. This review explores key molecular alterations in PDAC, while emphasizing differences between -mutated and -wild-type tumours. It assesses the practical application of precision medicine in clinical settings and outlines potential future directions with respect to PDAC. Actionable molecular targets are examined with the aim of enhancing our understanding of PDAC molecular biology. Insights from this analysis may contribute to a more refined and personalized approach to pancreatic cancer treatment, ultimately improving patient outcomes.
胰腺导管腺癌（PDAC）由于预后不佳、发病率上升和治疗选择有限，在患者管理方面面临重大挑战。在这方面，基于肿瘤分子特征进行个性化治疗的精准医学引起了极大关注。然而，目前的建议并未完全认可其广泛应用。本综述探讨了PDAC中的关键分子改变，同时强调了突变型和野生型肿瘤之间的差异。它评估了精准医学在临床环境中的实际应用，并概述了PDAC未来的潜在发展方向。通过研究可操作的分子靶点，旨在加深我们对PDAC分子生物学的理解。该分析的见解可能有助于形成更精细、个性化的胰腺癌治疗方法，最终改善患者的治疗效果。
